BRAVO
Clinical Trial Program
|
A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician’s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. |
Phase III
Status
Finished
Tumour subtype:
HR+, TNBC
Scenario
Locally Advanced or Metastatic
SPONSOR
PRINCIPAL INVESTIGATORS
Nick Turner, MD, PhD (Institute of Cancer Research, London)
Judith Balmaña, MD, PhD (Hospital Universitari Vall d’Hebron)
David Cameron, MD, PhD (University of Edinburgh Cancer Centre, IGMM, Western General Hospital, Edinburgh)
William Audeh, MD, PhD (Cedars-Sinai Medical Center)
